The purpose of this study is to determine whether continued administration of Drotrecogin Alfa (Activated) up to additional 72 hours - after the so far recommended 96 hour infusion period - results in a more rapid resolution of hypotension in severe septic patients.

Inclusion Criteria:

• Severe sepsis patients treated with 96 hour infusion of commercial Drotrecogin Alfa (Activated)
• Continue requirement of Vasopressor support after 96 hour commercial infusion

Exclusion Criteria:

• Patients require extensive surgical procedures within next 3 days
• Patients with platelet count below 30,000/mm3
• Patients receiving therapeutic heparin of 15,000 units/day and more
• Patients not expected to survive 24 days
• Patients contraindicated as to the country specific registration